IL-1β

Pro-inflammatory cytokine

Expression
elevated
Evidence level
established
Targeted by
Anakinra, Canakinumab

Role in pathogenesis

Central disease mediator: drives fever, rash, joint symptoms, CRP/SAA elevation, and systemic inflammation. CAPS is the prototypical IL-1β-driven disease. Dramatic response to IL-1 blockade proves its pathogenic role.

Targeting drugs (2)

DrugMechanismResponseLine
AnakinraIL-1 receptor antagonistSustained efficacy up to 5 years1st
CanakinumabAnti-IL-1β monoclonal antibody78-97% complete response1st

Sources (3)

DetailsGoldbach-Mansky R et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition · N Engl J MedDOI ↗
DetailsLachmann HJ et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome · N Engl J MedDOI ↗
DetailsPutnam CD et al. (2024) The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity · Immunol RevDOI ↗